Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORTH-REG Dwell-Time Study
2023-505936-37-00Phase 4Authorised
- Sponsor
- Aarhus University Hospital
- Start
- Jul 2023
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 4, randomised trial of BCG MEDAC in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Completion of full BCG induction and 12-month maintenance. Planned start Jul 2023; status: authorised.
02
Drugs
BCG MEDAC
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2023-505936-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505936-37-00.